Epstein-Barr Virus

EBV Succumbs to Genetic Manipulation

Published in Gene Therapy Weekly, July 17th, 1995

German researchers have developed a process that allows for a detailed genetic analysis of Epstein-Barr virus (EBV) with human gene therapy applications.

Although EBV viral genes are expressed in latently infected B lymphocytes and function in cellular growth control, genetic analysis has been cumbersome up to this point for two reasons. One, the viral genome is too large to permit genetic engineering; and two, human primary B lymphocytes, the only targets for infection by EBV in vitro, are intractable in culture and recalcitrant to DNA transfection.

Bettina Kempkes et al. overcame these problems by assembling all the essential EBV genes on a single...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry